TY - JOUR
T1 - Artificial intelligence-enabled decision support in nephrology
AU - Loftus, Tyler J.
AU - Shickel, Benjamin
AU - Ozrazgat-Baslanti, Tezcan
AU - Ren, Yuanfang
AU - Glicksberg, Benjamin S.
AU - Cao, Jie
AU - Singh, Karandeep
AU - Chan, Lili
AU - Nadkarni, Girish N.
AU - Bihorac, Azra
N1 - Funding Information:
T.J.L. was supported by the National Institute of General Medical Sciences (NIGMS) of the NIH under Award Number K23 GM140268. T.O.-B. was supported by grants K01 DK120784, R01 DK123078 and R01 DK121730 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), grant R01 GM110240 from NIGMS, grant R01 EB029699 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and grant R01 NS120924 from the National Institute of Neurological Disorders and Stroke (NINDS). B.S.G. was supported by grant R01MH121923 from the National Institute of Mental Health (NIMH), grants R01AG059319 and R01AG058469 from the National Institute for Aging (NIA) and grant 1R01HG011407-01Al from the National Human Genome Research Institute (NHGRI). G.N.N. is supported by grants R01 DK127139 from NIDDK and R01 HL155915 from the National Heart Lung and Blood Institute (NHLBI). L.C. was supported by grant K23 DK124645 from the NIDDK. A.B. was supported by grant R01 GM110240 from NIGMS, grants R01 EB029699 and R21 EB027344 from NIBIB, grant R01 NS120924 from NINDS and by grant R01 DK121730 from NIDDK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
B.S.G. has received consulting fees from Anthem AI and consulting and advisory fees from Prometheus Biosciences. K.S. has received grant funding from Blue Cross Blue Shield of Michigan and Teva Pharmaceuticals for unrelated work, and serves on a scientific advisory board for Flatiron Health. G.N.N. has received consulting fees from AstraZeneca, Reata, BioVie, Siemens Healthineers and GLG Consulting; grant funding from Goldfinch Bio and Renalytix; financial compensation as a scientific board member and adviser to Renalytix; owns equity in Renalytix and Pensieve Health as a cofounder and is on the advisory board of Neurona Health. The other authors declare no competing interests.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/7
Y1 - 2022/7
N2 - Kidney pathophysiology is often complex, nonlinear and heterogeneous, which limits the utility of hypothetical-deductive reasoning and linear, statistical approaches to diagnosis and treatment. Emerging evidence suggests that artificial intelligence (AI)-enabled decision support systems — which use algorithms based on learned examples — may have an important role in nephrology. Contemporary AI applications can accurately predict the onset of acute kidney injury before notable biochemical changes occur; can identify modifiable risk factors for chronic kidney disease onset and progression; can match or exceed human accuracy in recognizing renal tumours on imaging studies; and may augment prognostication and decision-making following renal transplantation. Future AI applications have the potential to make real-time, continuous recommendations for discrete actions and yield the greatest probability of achieving optimal kidney health outcomes. Realizing the clinical integration of AI applications will require cooperative, multidisciplinary commitment to ensure algorithm fairness, overcome barriers to clinical implementation, and build an AI-competent workforce. AI-enabled decision support should preserve the pre-eminence of wisdom and augment rather than replace human decision-making. By anchoring intuition with objective predictions and classifications, this approach should favour clinician intuition when it is honed by experience.
AB - Kidney pathophysiology is often complex, nonlinear and heterogeneous, which limits the utility of hypothetical-deductive reasoning and linear, statistical approaches to diagnosis and treatment. Emerging evidence suggests that artificial intelligence (AI)-enabled decision support systems — which use algorithms based on learned examples — may have an important role in nephrology. Contemporary AI applications can accurately predict the onset of acute kidney injury before notable biochemical changes occur; can identify modifiable risk factors for chronic kidney disease onset and progression; can match or exceed human accuracy in recognizing renal tumours on imaging studies; and may augment prognostication and decision-making following renal transplantation. Future AI applications have the potential to make real-time, continuous recommendations for discrete actions and yield the greatest probability of achieving optimal kidney health outcomes. Realizing the clinical integration of AI applications will require cooperative, multidisciplinary commitment to ensure algorithm fairness, overcome barriers to clinical implementation, and build an AI-competent workforce. AI-enabled decision support should preserve the pre-eminence of wisdom and augment rather than replace human decision-making. By anchoring intuition with objective predictions and classifications, this approach should favour clinician intuition when it is honed by experience.
UR - http://www.scopus.com/inward/record.url?scp=85128754216&partnerID=8YFLogxK
U2 - 10.1038/s41581-022-00562-3
DO - 10.1038/s41581-022-00562-3
M3 - Review article
C2 - 35459850
AN - SCOPUS:85128754216
VL - 18
SP - 452
EP - 465
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
SN - 1759-5061
IS - 7
ER -